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Probing the role of homomeric and heteromeric receptor
interactions in TGF-b signaling using small molecule dimerizers
Brent R. Stockwell and Stuart L. Schreiber 
Background: Transforming growth factor β (TGF-β) arrests many cell types in
the G1 phase of the cell cycle and upregulates plasminogen activator
inhibitor 1 (PAI-1). The type I (TGF-βRI) and II (TGF-βRII) TGF-β receptors
mediate these and other effects of TGF-β on target cells. TGF-β initially binds to
TGF-βRII and subsequently TGF-βRI is recruited to form a heteromeric
complex. TGF-βRI phosphorylates the downstream effectors Smad2 and
Smad3, leading to their translocation into the nucleus. Here, we explored the
role of receptor oligomerization in TGF-β signaling.
Results: We constructed fusion proteins containing receptor cytoplasmic tails
linked to binding domains for small-molecule dimerizers. In COS-1 cells,
recruitment of a soluble TGF-βRII tail to a myristoylated TGF-βRI tail promoted
Smad2 nuclear translocation. In mink lung cells, homo-oligomerization of a
myristoylated TGF-βRI tail in the presence of a myristoylated TGF-βRII tail
activated the PAI-1 promoter. Oligomerization of an acidic mutant of the
TGF-βRI tail in the absence of TGF-βRII activated the PAI-1 promoter and
inhibited the growth of mink lung cells.
Conclusions: Non-toxic, small molecules designed to oligomerize cytoplasmic
tails of TGF-β receptors at the plasma membrane can activate TGF-β signaling.
Although TGF-β normally signals through two receptors that are both necessary
for signaling, in one small-molecule system, a dimerizer activates signaling
through a single type of receptor that is sufficient to induce TGF-β signaling.
These methods of activating TGF-β signaling could be extended to signaling
pathways of other TGF-β superfamily members such as activin and the bone
morphogenetic proteins.
Background
Transforming growth factor β 1, 2 and 3 (TGF-β1, β2, β3)
are secreted, dimeric polypeptide signaling factors and
represent prototypical members of the TGF-β superfam-
ily, which includes activin and the bone morphogenetic
proteins (BMPs) [1]. Members of the TGF-β superfamily
have numerous activities on different cell types, including
in epithelial cells the ability to induce cell cycle arrest in
G1 and to upregulate extracellular matrix proteins such as
fibronectin and plasminogen activator inhibitor 1 (PAI-1)
[1]. The cellular effects of each TGF-β are dependent on
their binding to the extracellular domains of two types of
transmembrane serine/threonine kinase receptor [2–8],
known as type I (TGF-βRI) [9] and type II (TGF-βRII)
[10] receptors. Two other types of receptor, type III
(TGF-βRIII) [11] and type V (TGF-βRV) [12], may be
involved in TGF-β signaling, although an essential role
has not been established for either.
TGF-βRII is a constitutively active [13] homodimeric
serine/threonine kinase [10] that undergoes autophosphory-
lation on serine [14] and tyrosine residues [15]. TGF-βRII is
the upstream component in the signal transduction cascade
— TGF-β first binds to TGF-βRII and then subsequently
to TGF-βRI, recruiting it into the complex [13,16,17]. For
TGF-β2, binding to either receptor requires the presence of
both TGF-βRI and TGF-βRII [18], or both TGF-βRII and
TGF-βRIII [19]. TGF-βRII phosphorylates TGF-βRI on
serine residues in a glycine and serine-rich intracellular jux-
tamembrane region known as the GS box [13]. Receptor
transphosphorylation is unidirectional in that TGF-βRII
phosphorylates TGF-βRI but the converse does not occur
[13,18]. Studies using 32P-labeling and phosphopeptide
mapping suggest that TGF-βRI does not undergo
autophosphorylation in vivo, although it does in vitro [13,20].
Experiments with chimeric TGF-βRI constructs and a par-
tially constitutively active mutant of TGF-βRI that signals
in the absence of TGFβ−RII suggest that TGF-βRII is
responsible for activating TGF-βRI and that TGF-βRI
determines the specificity of response (that is, whether the
cell responds to BMP, TGF-β, or activin) [17,21–24].
Following receptor transphosphorylation, the intracellular
TGF-β effectors Smad2 and Smad3 transiently associate
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with TGF-βRI and are phosphorylated by this receptor
[25–29]. Phosphorylation of Smad2 and Smad3 occurs on
an SSXS consensus motif (in single-letter amino acid code)
on their carboxyl termini and this phosphorylation proba-
bly induces dissociation of the Smad substrate from 
TGF-βRI [26]. Smad6 and Smad7, both of which lack the
carboxy-terminal SSXS consensus sequence, antagonize
TGF-β superfamily signaling by associating stably with
either type I receptors [30,31] or Smad4 [32]. Phosphoryla-
tion of Smad2 and Smad3 is likely to be necessary for at
least some of the effects of TGF-β, because mutants of
Smad2 or Smad3 that cannot be phosphorylated by TGF-
βRI act as dominant-negative inhibitors of TGF-β signal-
ing [25–27,33]. After their phosphorylation, Smad2 and
Smad3 then associate with each other [27] and with Smad4,
a common Smad required for signaling by TGF-β, activin,
and BMP [28,34,35], to form a heteromeric complex that
translocates to the nucleus [27,28,36]. Fusion proteins con-
taining the DNA-binding domain of the yeast transcription
factor Gal4 fused to the BMP effector Smad1 [29,37,38] or
the TGF-β effector Smad2 have latent transcriptional acti-
vation activity that is unmasked by stimulation of BMP or
TGF-β signaling, respectively [37,39], indicating that
Smads can act as transcriptional activators. In the nucleus,
Smad2 interacts directly with FAST-1 [40], a winged helix
DNA-binding protein [41,42]. In some cases, Smads may
directly bind DNA and activate transcription [43]. As
FAST-1 binds to the activin-responsive element in the
Mix.2 promoter [41], and a fly Smad (named Mad) binds
the enhancer region of the vestigial gene in response to the
TGF-β family member decapentaplegic (Dpp), resulting
in vestigial expression [43], it is likely that activation and
nuclear translocation of Smad2, Smad3, and Smad4 causes
upregulation of TGF-β-responsive genes.
As TGF-βRII exists as a preformed homodimer on the
cell surface [44,45] and as TGF-β binds to the TGF-βRII
extracellular domain with a stoichiometry of 1:2 [46],
TGF-β probably binds to a preformed TGF-βRII homo-
dimer. Native gels of the active receptor complex reveal
the existence of higher order oligomers of TGF-βRI and
TGF-βRII [16]. TGF-βRI may bind to the
TGF-βRII2–TGF-β complex as a homodimer. It has been
suggested that TGF-βRI is a preformed homodimer and
that TGF-β induces the formation of a heterotetramer
containing one TGF-βRI homodimer and one TGF-βRII
homodimer [47]. Genetic evidence indicates that
TGF-βRI has two necessary functions and these functions
can be carried out by separate TGF-βRI molecules, con-
sistent with this heterotetramer model [48].
We sought to explore the mechanism of TGF-β receptor
activation by inducing the homo-oligomerization and
hetero-oligomerization of receptor cytoplasmic tails using
cell-permeable chemical inducers of dimerization (CIDs)
[49]. We aimed to determine the receptor oligomerization
events that are sufficient to activate downstream compo-
nents of the TGF-β pathway and to develop reagents that
can reveal the physiological functions of TGF-β signaling
pathways in transgenic organisms.
Results
Recruitment of a soluble TGF-bRII tail to a myristoylated
TGF-bRI tail causes Smad2 nuclear translocation
To monitor the level of receptor activation and the state of
TGF-β signaling, we used a fusion protein comprising green
fluorescent protein (GFP) and Smad2, referred to as
GFP–Smad2 (Figure 1). When expressed in COS-1 cells,
this protein is localized to the cytoplasm in the absence of a
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Schematic representation of constructs encoding small-molecule-
binding domain modules fused to TGF-β receptor cytoplasmic tails. The
following abbreviations are used: M, 14 amino acid myristoylation
sequence from c-Src; Fpk, G89P I90K double mutant of the 12 kDa
FK506-binding protein, FKBP12; (Fpk)3, three tandem copies of Fpk; A,
cyclophilin A; A*, the ATM triple mutant of cyclophilin A that binds
cyclosporin and some cyclosporin derivatives [70]; (A*)3, three tandem
copies of A*; B, the FKBP12–rapamycin-binding domain (FRB) [54]
(residues 2025–2114) of the FKBP12–rapamycin-associated protein,
FRAP; B*, triple mutant of FRB (FRB*) that binds both rapamycin and
its non-toxic variant methallylrapamycin [53]; GFP, S65T mutant of
green fluorescent protein; TI, residues 153–501 of the rat TGF-βRI R4;
TIT202D, T202D activated mutant of TI; TIT202D(KD), T202D, K230R
activated, kinase-dead double mutant of TI; TII, residues 193–567 of the
human TGF-βRII; TII(KD), K277R kinase-dead mutant of TII.
TGF-β signal and to the nucleus in the presence of a
TGF-β signal [50]. We created fusion proteins (Figure 1)
containing the TGF-β receptor intracellular domains that
could be inducibly associated using CIDs [49]. We con-
structed a fusion protein containing a myristoylation
sequence (M), a G89P,I90K (single-letter amino acid code)
double mutant (Fpk) [51] of the 12 kDa FK506-binding and
rapamycin-binding protein (FKBP12) and the rat TGF-βRI
[20] tail (TI), creating MFpkTI (Figure 1). We also fused the
TGF-βRII cytoplasmic tail to a triple mutant of the
FKBP12–rapamycin-binding (FRB) domain of the
FKBP12–rapamycin-associated protein (FRAP) [52] (FRB*:
the three mutations accommodate the large methallyl sub-
stituent of the ‘bumped’ rapamycin derivative, methallylra-
pamycin [53]) and to cyclophilin A (A), resulting in the
soluble protein B*ATII (Figure 1). We anticipated that
these constructs could be conditionally associated using the
heterodimerizers rapamycin [54] and its non-toxic and non-
immunosuppressive synthetic variant methallylrapamycin
[53]. The ability of the CIDs to cause the receptors to inter-
vene in the TGF-β signaling pathway was determined by
monitoring the subcellular localization of GFP–Smad2.
Transfection of COS-1 cells with MFpkTI, B*ATII and
GFP–Smad2 resulted in a non-nuclear localization pattern
for GFP–Smad2 (Figure 2a). Treatment of these cells with
30 nM rapamycin or methallylrapamycin, both of which
bind the mutant FRB* domain [53], resulted in transloca-
tion of GFP–Smad2 to the nucleus (Figure 2a), by recruit-
ing the soluble TGF-βRII construct to the
membrane-localized TGF-βRI construct. Furthermore,
treatment with the FKBP12 antagonist FK506M [49] had
no effect on the distribution of GFP–Smad2 (Figure 2a).
To confirm that binding of the heterodimerizers rapamycin
and methallylrapamycin to the FRB* domain is required
for the nuclear translocation of GFP–Smad2, we replaced
the FRB* domain in B*ATII with the wild-type FRB
domain (B), generating the construct BATII (Figure 1).
COS-1 cells cotransfected with plasmids encoding
MFpkTI, BATII, and GFP–Smad2 again showed a cytoplas-
mic distribution of GFP–Smad2 (Figure 2b). Treatment of
these cells with 30 nM rapamycin, but not 30 nM methal-
lylrapamycin or 30 nM FK506M, resulted in translocation
of GFP–Smad2 into the nucleus (Figure 2b). This result is
consistent with methallylrapamycin having a > 100-fold
higher EC50 relative to rapamycin in a transcription activa-
tion assay using FKBP12 and wild-type FRB [53].
Rapamycin, but not methallylrapamycin, is able to bind
BATII and recruit it to MFpkTI (Figure 3a). We also tested
a kinase-dead mutant of TGF-βRII, B*ATII(KD)
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Figure 2
Recruitment of a soluble TGF-βRII cytoplasmic
tail to a membrane-localized TGF-βRI
cytoplasmic tail results in GFP–Smad2 nuclear
translocation. The left column shows the GFP
signal (fluorescein isothiocyanate filters), the
center column shows the location of the
Hoechst-33258-stained nucleus (no filters)
and the right column shows a phase contrast
image of the same cell. (a) With FRB*, both
methallylrapamycin and rapamycin induce
GFP–Smad2 nuclear translocation. COS-1
cells were transfected with plasmids encoding
GFP–Smad2, B*ATII and MFpkTI and were
either left untreated (no treatment) or
stimulated for 1 h with 30 nM
methallylrapamycin (Rap*), 30 nM rapamycin
(Rap) or 30 nM FK506M. (b) With wild-type
FRB, rapamycin but not methallylrapamycin
induces GFP–Smad2 translocation. COS-1
cells were transfected with plasmids encoding
GFP–Smad2, BATII and MFpkTI and stimulated
as for (a). (c) Recruitment of a kinase-dead
type II receptor does not induce GFP–Smad2
nuclear translocation. COS-1 cells were
transfected with plasmids encoding
GFP–Smad2, B*ATII(KD) and MFpkTI and
stimulated as for (a). (d) Dose-dependent
translocation of GFP–Smad2 in response to
the heterodimerizer methallylrapamycin.
COS-1 cells were transfected with plasmids
encoding GFP–Smad2, B*ATII and MFpkTI as
for (a) and stimulated for 1 h with the indicated
concentrations of methallylrapamycin.
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(Figure 1). In this case, neither rapamycin nor methallylra-
pamycin treatment induced the nuclear accumulation of
GFP–Smad2 (Figure 2c), indicating that the kinase activity
of the type II receptor is required for GFP–Smad2 translo-
cation. Finally, when we tested the dose response in this
assay, we observed significant nuclear accumulation of
GFP–Smad2 with just 10 nM methallylrapamycin
(Figure 2d).
Homo-oligomerization of a TGF-bRI tail in the presence of
a kinase-active TGF-bRII tail activates the PAI-1 promoter
We wanted to homo-oligomerize or to hetero-oligomerize
directly the cytoplasmic tails of the TGF-β receptors at
the inner leaflet of the plasma membrane using CIDs. To
this end, we generated a myristoylated construct contain-
ing three tandem Fpk domains and the cytoplasmic tail of
the type I receptor (M(Fpk)3TI) as well as a myristoylated
construct with three cyclophilin domains and the cytoplas-
mic tail of TGF-βRII (M(A*)3TII; Figure 1). We antici-
pated that by using the homodimerizer FK1012H2 [55]
(for all chemical structures, see Supplementary material
published with this paper on the internet), we would
oligomerize M(Fpk)3TI, whereas using the homodimerizer
CsA2 [56] we would oligomerize M(A*)3TII and using the
heterodimerizer FKCsA [57] we would form a hetero-
oligomeric complex containing both M(Fpk)3TI and
M(A*)3TII (Figure 4a). Using this strategy, we were able
to homo-oligomerize one receptor tail in the presence of
the other receptor tail.
To test these constructs, we used a transient transfection
assay developed by Wrana et al. [58], in which the
luciferase reporter gene is fused downstream of three
phorbol ester responsive elements and the PAI-1 pro-
moter–enhancer sequence. In mink lung cells, this
reporter plasmid (p3TPLux) is activated upon stimulation
of transfected cells with TGF-β [58]. We transfected
Mv1Lu mink lung epithelial cells with plasmids encoding
M(Fpk)3TI, M(A*)3TII and p3TPLux and tested the effect
on reporter gene activity of the dimerizers FK1012H2,
CsA2, FKCsA and the control FKBP12 antagonist
FK506M. The heterodimerizer FKCsA modestly acti-
vated p3TPLux whereas FK1012H2 more potently acti-
vated this reporter and CsA2 and FK506M had no effect
(Figure 4b). The EC50 for FK1012H2-induced activation
of p3TPLux was 20 nM (Figure 4c). These data suggest
that homo-oligomerization of the TGF-βRI cytoplasmic
tail activates TGF-β signaling. However, activation of
p3TPLux by FK1012H2 required the presence of both
TGF-βRI and TGF-βRII kinase-active tails (Figure 4c
and data not shown). The nature of the binding domain
(FRB, cyclophilin A or FKBP12) on the type II receptor
did not affect activation by FK1012H2 (data not shown).
These results suggest that the TGF-βRI and TGF-βRII
tails might transiently associate to some extent, especially
as they bind to each other in the yeast two-hybrid interac-
tion assay [59] and in coimmunoprecipitation experiments
[60]. In this case, FK1012H2 would be aggregating both
activated and unactivated TGF-βRI tails, although only
the activated TGF-βRI oligomers would signal. To sim-
plify the interpretation of this result, we searched for a
TGF-βRII-independent method of activating TGF-βRI.
A mutant TGF-bRI tail is activated by oligomerization in the
absence of TGF-bRII
Wieser et al. [22] reported that a T204D mutant of human
TGF-βRI is partially constitutively active, even in the
absence of TGF-βRII. Furthermore, erythropoietin (Epo)-
induced homodimerization of an Epo receptor extracellular
domain fused to the human TGF-βRI(T204D) cytoplas-
mic domain results in increased growth inhibition of stably
transfected Ba/F3 cells [47]. We tested the effect of the
corresponding T to D mutation (T202D) in the rat TGF-
βRI (known as R4), in the context of M(Fpk)3TI, by gener-
ating the construct M(Fpk)3TIT202D (Figure 1). This
construct was not constitutively active, but was activated
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Figure 3
A model for heterodimerizer-induced activation of TGF-β signaling 
(a) Recruitment of a soluble TGF-βRII to a membrane-localized TGF-βRI
with rapamycin. Rapamycin is a natural heterodimerizer by virtue of its
ability to bind both FKBP12 and FRB. The derivative methallylrapamycin
has a synthetic ‘bump’ that prevents it from binding to wild-type FRB,
and so methallylrapamycin cannot recruit the FRB–TGF-βRI fusion
protein. (b) The triple mutant FRB* binds both methallylrapamycin and
rapamycin. Thus, both molecules are able to function as heterodimerizers
with the FKBP12 fusion and soluble FRB* fusion proteins.
(b)
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by oligomerization with FK1012H2, even in the absence of
TGF-βRII (Figure 5a). We ensured that endogenous
TGF-βRII was not activating M(Fpk)3TIT202D by using
DR26 cells, which have a defective endogenous TGF-
βRII [58]. DR26 cells transfected with p3TPLux and a
plasmid encoding M(Fpk)3TIT202D and treated with the
dimer FK1012H2, but not the monomeric antagonist
FK506M, showed activation of p3TPLux (Figure 5a).
To ensure that activation of M(Fpk)3TIT202D by FK1012H2
was due to oligomerization and not simple binding to
FKBP12, we performed a competition experiment with
FK506M. Simultaneous treatment of M(Fpk)3TIT202D and
p3TPLux-transfected DR26 cells with FK1012H2 and an
excess of FK506M did not activate p3TPLux (Figure 5b),
most probably because the monomer can compete with the
dimer for binding to FKBP12 and thereby prevent
FK1012H2-induced oligomerization of M(Fpk)3TIT202D. To
demonstrate further that TGF-βRI cytoplasmic tail
homodimerization resulted in activation of p3TPLux in the
absence of FKBP12 ligands, we generated the construct
MATIT202D, in which there are no FKBP12 domains, but
simply one cyclophilin domain fused to the T202D mutant
of the cytoplasmic tail of TGF-βRI. This construct is some-
what constitutively active [50], but was activated further by
treatment with the dimeric molecule CsA2, but not the
monomeric antagonist CsAM (Figure 5c).
We have also shown that the construct MFpkTIT202D, con-
taining only one Fpk domain, can be activated by high
concentrations of FKBP12 antagonists such as FK506M
[50]. This construct was more potently activated by
FK1012H2, a homodimerizer (Figure 5d). However, the
single FKBP12 construct MFpkTIT202D showed different
dose-response curves for FK506M and FK1012H2
(Figure 5d). The dimerizer FK1012H2 had an EC50 of
10–20 nM, as was the case when a TGF-βRII construct
was cotransfected with a plasmid encoding M(Fpk)3TI.
This is consistent with a gain-of-function induced by
receptor dimerization with FK1012H2, whereas the results
with the antagonist FK506M, having an EC50 of
300–500 nM, are consistent with a loss-of-function of the
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Oligomerization of TGF-βRI in the presence of a kinase-active
TGF-βRII activates TGF-β signaling in mink lung cells. (a) A cartoon
diagram of dimerizer-induced oligomerization of the TGF-β receptor
cytoplasmic tails. Coexpression of the two receptor tails results in
partial activation and phosphorylation (P) of the type I receptor,
possibly because of transient associations between TGF-βRI and
TGF-βRII cytoplasmic domains. FK1012H2 oligomerizes MFpkTI, CsA2
oligomerizes MA*TII and FKCsA hetero-oligomerizes the two receptor
constructs. Single binding domain constructs are shown in the cartoon
for simplicity, although some constructs described in the text have
three tandem binding domains. (b) Type I receptor oligomerization
causes activation of the TGF-β-responsive reporter construct p3TPLux.
Mv1Lu cells were transiently transfected with the reporter p3TPLux
and either plasmids encoding M(Fpk)3TI and M(A*)3TII or pBluescript.
Transfected cells were treated with the indicated compounds and
luciferase activity was measured. (c) TGF-β signaling is initiated at low
concentrations of the dimerizer FK1012H2. Dose-response curve for
FK1012H2-induced activation of the reporter p3TPLux. Mv1Lu cells
were transfected with p3TPLux, and plasmids encoding M(Fpk)3TI and
either kinase-active M(A*)3TII or kinase-dead M(A*)3TII(KD); the cells
were stimulated with the indicated concentrations of FK1012H2.
fused FKBP12 as a repressor of TI. Neither the kinase-
dead construct M(Fpk)3TIT202D(KD) nor the wild-type
construct M(Fpk)3TI was activated by FK1012H2
(Figure 5e). Activation by FKBP12 antagonists, such as
FK506M, was not observed with the triple FKBP12 con-
structs (Figure 5a) possibly because the three intramolec-
ular Fpk domains either prevent spontaneous TGF-βRI
homomeric interactions or cannot be competed away
effectively by FKBP12 antagonists.
We also tested whether the myristoylation sequence was
required for activation of MFpkTIT202D by FK1012H2. We
replaced the myristoylation sequence with an amino-termi-
nal FLAG epitope tag, generating the soluble construct
FpkTIT202D. In the presence of 100 nM FK1012H2, the
soluble construct FpkTIT202D had half of the activity of the
membrane-localized construct MFpkTIT202D (data not
shown). We also found that heterodimerization of soluble
TGF-βRI and TGF-βRII constructs with rapamycin could
induce partial GFP–Smad2 nuclear translocation in COS-1
cells (data not shown). These results indicate that myristoy-
lation increases the magnitude of dimerizer-induced activa-
tion of TGF-β signaling. However, we cannot determine
from these experiments whether the soluble receptor con-
structs spontaneously associate with the plasma membrane
or whether a weak TGF-β signal can emanate from the
cytoplasm. Similar findings were reported in studies of
small-molecule-activated conditional alleles of receptor
tyrosine kinases [61].
The hallmark of TGF-β action in mink lung cells is G1
cell cycle arrest. To confirm that small-molecule dimeriz-
ers induce the chimeric TGF-β receptors described in this
report to inhibit cell division, a mink lung cell line stably
expressing M(Fpk)3TIT202D was prepared. Treatment of
this cell line with the homodimerizer FK1012H2 resulted
in potent growth inhibition with an EC50 of 200 pM
(Figure 6a). In contrast, the dimerizer had no effect on
proliferation of the parent cell line Mv1Lu (Figure 6a).
The magnitude of growth inhibition was comparable to
that achieved by TGF-β itself in the same cell line
(Figure 6b). The lower EC50 for growth inhibition com-
pared with p3TPLux activation probably represents the
different sensitivities of these two assays, that is, 50%
growth inhibition may be observed when 0.1% of receptors
are activated whereas 50% reporter gene activation might
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Figure 5
A mutant TGF-βRI is activated by homo-
oligomerization in the absence of TGF-βRII.
(a) The M(Fpk)3TIT220D fusion protein is
activated by homo-oligomerization. DR26 mink
lung cells, lacking endogenous TGF-βRII,
were transfected with plasmids encoding
M(Fpk)3TIT202D and p3TPLux and stimulated
with the indicated concentrations of FK506M
or FK1012H2. Normalized luciferase activity
produced is shown. (b) Competition with
FK506M prevents activation by FK1012H2.
DR26 cells were transfected with
M(Fpk)3TIT202D or the kinase-dead
M(Fpk)3TIT202D(KD) and either left untreated or
treated with 30 nM FK1012H2 or treated with
both 30 nM FK1012H2 and 1 µM FK506M.
(c) MATIT202D is activated by
homodimerization. DR26 cells were
transfected with p3TPLux and a plasmid
encoding MATIT202D and then either left
untreated or treated with 1 µM CsA2 or 1 µM
CsAM. (d) The MFpkTIT202D fusion protein is
potently activated by dimerization and
modestly activated by FKBP12 antagonists.
DR26 cells were transfected with p3TPLux
and a plasmid encoding MFpkTIT202D and
treated with the indicated concentrations of
the dimerizer FK1012H2 or the FKBP12
antagonist FK506M. (e) In the absence of
TGF-βRII, only the mutant TGF-βRI is
activated by oligomerization. DR26 cells were
transfected with p3TPLux and a plasmid
encoding M(Fpk)3TIT202D, M(Fpk)3TIT202D(KD) or
M(Fpk)3TI and stimulated with the indicated
concentrations of the dimerizer FK1012H2.
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only be observed when 5% of receptors are activated.
TGF-β1 itself has an EC50 of 25 pM for p3TPLux activa-
tion and 0.2 pM for growth inhibition (data not shown).
Discussion
There has been considerable interest in determining the
minimal stoichiometric requirements of an active TGF-β
receptor signaling complex. As TGF-βRII transphospho-
rylates and coimmunoprecipitates with TGF-βRI in a
TGF-β-dependent fashion [13,18], and as TGF-βRI can
be crosslinked to 125I-labeled TGF-β only in the presence
of TGF-βRII [59], it is likely that TGF-β directly dimer-
izes TGF-βRI and TGF-βRII. In addition, the observa-
tions that TGF-βRI and TGF-βRII are both
biosynthesized and degraded at different rates [62,63],
and that each receptor can be expressed stably on the cell
surface in the absence of the other receptor [13], indicate
that in mink lung cells, TGF-βRI and TGF-βRII do not
exist in stable preformed heteromeric complexes.
Through the ability of TGF-β to bind the extracellular
domains of the two receptors simultaneously, the intracel-
lular kinase domains of the receptors are brought into
close proximity, thereby increasing the rate of the
transphosphorylation reaction involving these domains.
We have tested this model by directly dimerizing the
cytoplasmic effector domains of TGF-βRI and TGF-βRII
using the small-molecule heterodimerizers rapamycin and
methallylrapamycin. Direct association of the cytoplasmic
domains of the two receptors in this manner induced acti-
vation of a downstream signaling event — Smad2 nuclear
translocation. This effect, as expected, was dependent on
the kinase activity of TGF-βRII, indicating that the role
of receptor heterodimerization is to increase the rate of the
transphosphorylation reaction.
Several reports, including those describing fusion proteins
of the cytoplasmic domain of TGF-βRI and 
TGF-βRII with the extracellular domain of either the
granulocyte-macrophage colony stimulating factor α and β
receptors [64] or the Epo receptor [47] have demonstrated
that heterodimerization is a necessary step in TGF-β signal
transduction [65]. Similarly, in our assays, homo-oligomer-
ization of TGF-βRI or TGF-βRII fusion proteins
expressed separately did not result in signaling activity
(Figures 4c,5e and data not shown). In contrast, in the pres-
ence of the TGF-βRII tail, homo-oligomerization of the
TGF-βRI tail caused activation of TGF-β signaling
(Figure 4b). This effect can be explained by assuming a
transient association between TGF-βRI and TGF-βRII
tails, at least in the chimeric constructs used in our studies,
which results in activation of TGF-βRI. This assumption is
consistent with the observation that the cytoplasmic
domains of the receptors signal constitutively when over-
expressed together [50] and interact in yeast two-hybrid
assays [59] and coimmunoprecipitation experiments [60].
The full-length receptors, containing transmembrane and
extracellular domains, associate transiently in mink lung
cells [13] but do not signal constitutively unless highly
overexpressed. The ability to oligomerize one receptor in
the presence of the other has allowed us to discern the
importance of TGF-βRI oligomerization in TGF-β signal-
ing. As TGF-βRI oligomerization is effective only in the
presence of either TGF-βRII or an activating T202D
mutation in TGF-βRI, and as it is known that TGF-βRII
must phosphorylate and activate TGF-βRI, it is logical to
conclude that either subsequent to or concomitant with
TGF-βRII transphosphorylation of TGF-βRI, dimeriza-
tion or oligomerization of TGF-βRI occurs.
We were not able to study the role of homomeric interac-
tions in the GFP–Smad2 translocation assay because of the
problem of intrinsic protein–protein interactions described
above. We assume that TGF-βRI homomeric interactions
are taking place constitutively in this assay, thereby remov-
ing the need to induce such interactions specifically. It has
been reported that when transiently transfected, both
TGF-βRI and TGF-βRII exist as homodimers on the
surface of COS-1 cells [16]. However, in mink lung epithe-
lial cells, lower expression levels result from the same tran-
siently transfected plasmids. As a result, homo-
oligomerization of a TGF-βRI cytoplasmic domain acti-
vated TGF-β signaling in this cell line (Figure 4b,c). We
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Figure 6
The dimerizer FK1012H2 inhibits the growth
of a stably transfected mink lung cell line. 
(a) Wild-type mink lung Mv1Lu cells and a
stably transfected derivative containing the
integrated construct M(Fpk)3TIT202D were
sparsely seeded and treated with the
indicated concentrations of the homodimerizer
FK1012H2 in 1% serum. The number of live
cells present at the end of the experiment is
plotted. (b) The same procedure as for (a)
was used, except the stable cell line was
either left untreated or treated with 100 nM
FK1012H2 or 100 pM TGF-β1.
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also demonstrated that M(Fpk)3TIT202D oligomerization, in
the absence of a type II TGF-β receptor, is sufficient to
activate TGF-β signaling in Mv1Lu cells (Figure 5a,b,e).
These results imply that TGF-βRI homomeric interactions
are likely to be necessary in the natural system. Although
we were not able to observe synergistic activation by
adding heterodimerizers and homodimerizers simultane-
ously (data not shown), our results involving TGF-βRI
oligomerization strengthen the hypothesis that TGF-β
signals through a heterotetrameric receptor complex rather
than a heterodimeric complex [16,47,48].
The T202D mutation in TGF-βRI removed the require-
ment for co-expression of TGF-βRII in the reporter gene
assay (Figure 5a), but not in the GFP–Smad2 translocation
assay (data not shown). This seems to imply that the
T202D mutation complements TGF-βRII deficiency for
PAI-1 upregulation but not for Smad2 translocation. There
is already evidence that downstream effects of TGF-β can
be uncoupled at the level of TGF-βRI by mutation of spe-
cific serine or threonine residues. An S165E mutation in
TGF-βRI led to an increase in growth-inhibitory activity
and in extracellular matrix protein production, but to a
decrease in apoptotic activity, and had no effect on induc-
tion of reporter gene activity [66]. Similarly, S172A or
T176A mutations in TGF-βRI impaired the growth-
inhibitory activity but not the extracellular matrix-produc-
ing activity of the receptor [67]. Although it has been
reported that a dominant-negative version of Smad2
blocks activation of p3TPLux [26], this does not demand
that Smad2 translocation is necessary for p3TPLux activa-
tion. To address this question, Smad2-deficient cells are
needed to test activation of p3TPLux, similar to the
studies in Smad4-deficient cells for investigating the role
of Smad4 in p3TPLux activation [34]. However, the
inability of the T202D mutation to complement com-
pletely TGF-βRII deficiency in the GFP–Smad2 translo-
cation assay may reflect the fact that this mutation is only a
partial mimic of TGF-βRII phosphorylation [22] and that
these two assays may have different sensitivities and
threshold levels. In addition, all of the endogenous Smad2
may translocate in mink lung cells in the presence of the
T202D mutant, whereas only a fraction of the
GFP–Smad2 protein overexpressed by cotransfection
translocates in the COS-1 cell assay. To resolve this issue,
we are currently studying stably transfected mink lung
cells that express M(Fpk)3TIT202D to determine whether
endogenous Smad2 translocates in response to FK1012H2,
and to determine the mechanism of FK1012H2-dependent
signaling through the M(Fpk)3TIT202D receptor in general.
In the current study, these stably transfected cells were
examined for their ability to undergo FK1012H2-induced
cell growth arrest, in comparison with the actions of
TGF-β on the parental cell line. We found that this cell
line undergoes growth inhibition in the presence of the
dimerizer FK1012H2 with an EC50 of 200 pM (Figure 6a)
and that the level of growth inhibition is comparable to
that achieved with TGF-β in the same cell line
(Figure 6b). Luo and Lodish [47] found that Epo-induced
homodimerization of a fusion protein comprising the extra-
cellular domain of the Epo receptor and the intracellular
domain of human TGF-βRI containing an activating
T204D mutation caused growth inhibition of Ba/F3-trans-
fected cells. Together, these results indicate that this
acidic mutation can complement the absence of
TGF-βRII in TGF-βRI-induced growth inhibition.
An important and unresolved issue is the mechanistic role
of TGF-βRI homodimerization or homo-oligomerization.
What is the immediate effect of TGF-βRI dimerization?
One possibility is that upon dimerization, TGF-βRI
autophosphorylates in trans, in analogy to the protein tyro-
sine kinase receptors. However, 32P-labeling experiments
have suggested that wild-type TGF-βRI does not undergo
autophosphorylation in vivo [13], although it does in vitro
[68]. Another possibility is that TGF-βRI homodimeriza-
tion does not involve phosphorylation per se, but rather
creates a docking site for downstream effectors such as
Smad2 or Smad3, which must then be phosphorylated by
TGF-βRI. Although we have ruled out a requirement for
the mink type II TGF-β receptor phosphorylating the
M(Fpk)3TIT202D protein by using DR26 cells, we cannot
rule out the possibility that other type II receptors, such as
the activin type II receptor, are sufficiently promiscuous
to phosphorylate the mutant chimeric type I receptor GS
box. Nevertheless, we have demonstrated that two of the
hallmarks of TGF-β signaling, namely growth inhibition
and activation of the PAI-1 promoter, are induced by
oligomerization of M(Fpk)3TIT202D. These results suggest
that oligomerization of this single chimeric protein may
activate all downstream effects of TGF-β. We are cur-
rently exploring further mechanistic aspects of small-mol-
ecule-induced signaling through this receptor.
Conclusions
We have demonstrated that a small-molecule-induced
heteromeric interaction between cytoplasmic tails of
TGF-βRI and TGF-βRII fusion proteins is sufficient for
inducing Smad2 nuclear translocation. This translocation
requires both receptors and does not result from two sepa-
rate pathways each dependent on just one of the recep-
tors. We have also shown that homo-oligomerization of the
TGF-βRI cytoplasmic tail induces activation of TGF-β
signaling in mink lung cells, either with the wild-type
TGF-βRI tail in the presence of a kinase-active
TGF-βRII tail, or with a T202D mutant of the TGF-βRI
tail in the absence of a TGF-βRII tail. Oligomerization of
this mutant TGF-βRI construct resulted in growth inhibi-
tion of a stable cell line. This suggests that in the natural
system, TGF-βRI homomeric interactions may play an
essential role in transducing the TGF-β signal. Further-
more, we have developed several different methods of
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conditionally activating TGF-β signaling using small
membrane-permeable dimerizers and designed chimeric
variants of the TGF-β receptors. These methods of acti-
vating TGF-β signaling may be powerful in transgenic
organisms expressing the variant receptors, providing a
unique means to study the relevance of this pathway to
physiological events and disease processes [69].
Materials and methods
DNA constructions
All constructs were prepared and expressed in the mammalian expres-
sion vector pBJ5.1. R4 was obtained from Patricia Donahoe. TGF-
βRI(T204D), TGF-βRII and p3TPLux were obtained from Joan
Massague. Murine Smad2 (pcsMadr2) was obtained from Richard
Harland [36]. The plasmids pBJ5.1-EgBEu and pBJ5.1-EgB*VEu (Eg
and Eu represent FLAG and influenza epitope tags, respectively) were
obtained from Stephen Liberles. The construction of MFpkTI, M(Fpk)3TI,
MFpkTIT202D, M(Fpk)3TIT202D, MATIT202D, M(Fpk)3TIT202D(KD), MATII,
MATII(KD) and GFP–Smad2 is described elsewhere [50] and in the
Supplementary material. BATII, B*ATII and B*ATII(KD) were constructed
by digesting pBJ5.1-EgBEu, pBJ5.1-EgB*VEu or pBJ5.1-EgB*VEu with
SalI and EcoRI and ligating in the XhoI, EcoRI fragment of MATII, MATII
or MATII(KD), respectively.
Luciferase and GFP–Smad2 translocation assay
Luciferase and GFP–Smad2 translocation assays were performed as
described elsewhere [50] and in the Supplementary material.
Growth inhibition assay
The wild-type Mv1Lu mink lung cell line or the stable cell line containing
M(Fpk)3TIT202D was seeded in 6-well clusters (20,000 cells per well)
and allowed to attach overnight in 10% serum. Media was changed to
1% FBS with or without TGF-β or FK1012H2. After 4 days, the cells
were washed, trypsinized and counted. All experiments were per-
formed in triplicate and repeated at least twice.
Supplementary material
Additional figures depicting the chemical structures of the small mol-
ecules used in these experiments and a cartoon diagram of growth inhi-
bition in the stable cell line are published with this paper on the
internet. Complete experimental details for assays and plasmid con-
structions are also published as Supplementary material.
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Materials and methods
Plasmid construction
All constructs were prepared and expressed in the mammalian expres-
sion vector pBJ5.1. R4, the rat TGF-βRI, was obtained from Patricia
Donahoe and Tongwen Wang. The cDNA clones for the T204D mutant
of human TGF-βRI and wild-type human TGF-βRII as well as the
p3TPLux reporter were obtained from Joan Massague. M(Fpk)3Eu,
MFEu and MFpkEu were reported previously [14,20]. The pGEX2TK-
Awt plasmid was generated previously (Karen Liu and S.L.S., unpub-
lished). The S65T mutant of green fluorescent protein (J), was obtained
from the plasmid JC3E (Martin Pruschy and S.L.S., unpublished). The
murine Smad2 cDNA (pcsMadR2) was obtained from Richard Harland
[23]. MAEu was generated by ligating the XhoI–SalI fragment of
pGEX2TK-Awt into XhoI, SalI-digested MFpkEu. TI was obtained by
PCR amplification of residues 153–501 of R4 using primers Hp8 (5'-
GCC ATA ACC GCA CTG TCA TTC TCG AGC ACC ACC GCG
TGC CA-3') and Hp12 (5'-GG AAT GTC TAG AGA ATTC TTA CAT
TTT GAT GCC TTC CTG TTG G-3'). The PCR product was sub-
cloned into pBS3, a pBluescript IISK- derivative in which the KpnI site
was destroyed by Klenow fill-in and blunt-end ligation, to create pBS3-
TI. This and all other PCR products were sequenced using dideoxy
sequencing on both strands to ensure that no unwanted mutations had
been introduced. The TI fragment was subcloned into the pBJ5.1-
based expression vectors MAEu, MFpkEu, and M(Fpk)3Eu with XhoI and
EcoRI sites, to generate MATI, MFpkTI and M(Fpk)3TI, respectively. The
TIT202D fragment was generated with an amino-terminal FLAG epitope
tag by overlap extension PCR using R4 as template and primers B286-
1 (5'-TTA GGT ACC CTC GAG GAT TAT AAA GAT GAC GAT GAT
AAA CAC CAC CGC GTG CCA AAT-3'), B286-2 (5'-GCT TTC TTG
TAG CAC AAT GTC CCT TGC AAT TGT TCT TTG AAC AAG C-3'),
B286-3 (5'-GAC ATT GTG CTA CAA GAA AGC ATC GGC-3') and
B286-6 (5'-TTC CTT GGG TAC CAA CAA TCT CCA TG-3') and sub-
cloned into pBS3-TI with XhoI and KpnI to generate pBS3-TIT202D. The
TIT202D fragment was subcloned into pBJ5.1-MFpkEu, pBJ5.1-MFpkEu
and pBJ5.1-MAEu with XhoI and EcoRI to generate pBJ5.1-
MFpkTIT202D, pBJ5.1-M(Fpk)3TIT202D and pBJ5.1-MATIT202D, respectively.
TIT202D(KD) was generated by overlap extension PCR using pBS3-
TIT202D as template and primers B286-1, B286-4 (5'-CTT CTC TAG
AAG AGA ATA TCC TCA CGG CAA CTT CTT CTC-3'), B286-5 (5'-
AGG ATA TTC TCT TCT AGA GAA GAA CGT TCA TGG-3') and
B286-6. The PCR product was subcloned into pBS3-TI with XhoI and
KpnI to generate pBS3-TIT202D(KD) and the TIT202D(KD) fragment was
subcloned into pBJ5.1-MFpkEu and pBJ5.1-M(Fpk)3Eu with XhoI and
EcoRI to generate pBJ5.1-MFpkTIT202D(KD) and pBJ5.1-
M(Fpk)3TIT202D(KD), respectively. A general GFP expression vector
pBJ5.1-JEg was generated from pBJ5.1-JC3Eu by replacing the XhoI,
EcoRI fragment with a new fragment formed by annealing and ligating
oligos B92-1 (5'-TCG AGG GGG ATT ATA AAG ATG ATG ATG ATA
AAG TCG ACG GGG CAA- CAG-3') and B92-2 (5'-AAT TCT GTT
GCC CCG TCG ACT TTA TCA TCA TCA TCT TTA TAA TCC CCC-
3'). Murine Smad2 was amplified by PCR using pcsMADr2 as template
and primers B214-1 (5'-TTT CTC GTC GAC ATG TCG TCC ATC
TTG CCA TTC ACT CCG-3') and B214-2 (5'-TTT CTC GAA TTC TTA
CGA CAT GCT TGA GCA TCG CAC TGA AGG-3') and subcloned
into pBJ5.1-JEg using SalI and EcoRI to generate pBJ5.1-JEgSmad2
(referred to as GFP–Smad2 in the text). TGF-βRII was subcloned into
pBluescriptIISK- (Stratagene) with BamHI to generate pBS-TGF-βRII.
Residues 193–567 (up to the carboxyl terminus) of TGF-βRII were
amplified by PCR using pBS-TGF-βRII as template and primers B5 (5'-
CTA CTG CTA CCG CGT TAA CCT CGA GCG GCA GCA GAA
GCT GAG-3') and B4 (5'-GGT GAG AGG GGC AGC CTC TCT AGA
CAT GCC CAG CCT GCC CCA TAA GAG CTA GTC GAC TTT
GGT AGT GTT TAG GG-3'). The XhoI, SalI-digested PCR product
was first subcloned into pBluescriptIISK to generate pBS-TII and then
subcloned into the SalI site of pBJ5.1-MAEu or pBJ5.1-M(A*)3Eg to
generate pBJ5.1-MATII or pBJ5.1-M(A*)3TII, respectively. A kinase-dead
K277R mutant of TII (TII(KD)) was generated by PCR amplification
using primers B5 and B53-1 (5'-TTC ATC GGA TCC TGA CTG CCA
CTG TCT CAA ACT GC-3'), digestion with XhoI and BamHI and sub-
sequent ligation into XhoI, BglII-digested pBS-TII. The XhoI, SalI frag-
ment TII(KD) was subcloned into pBJ5.1-MAEu or pBJ5.1-M(A*)3TII to
generate pBJ5.1-MATII(KD) and pBJ5.1-M(A*)3TII(KD), respectively.
GFP–Smad2 translocation assay 
COS-1 cells were obtained from Patricia Donahoe and maintained in
Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin G sodium and
100 µg/ml streptomycin sulfate. For the GFP–Smad2 translocation
assay, 1.3 × 105 COS-1 cells were seeded on coverslips in 8 well
dishes. For transfection of each coverslip, 300 ng GFP–Smad2,
850 ng type I receptor (e.g. MFpkTI) and 850 ng type II receptor (e.g.
MATII) were mixed with 5.5 µl 2 mg/ml Lipofectamine (GibcoBRL) in
1.0 ml phenol red free and serum free DMEM (VDMEM), incubated at
room temperature for 30 min and then added to a coverslip which had
been washed twice with VDMEM. The cells were incubated with the
DNA/Lipofectamine mixture for 4 h at 37° C with 5% CO2 and then
washed twice with VDMEM and incubated 16–20 h in growth medium
at 37°C with 5% CO2. At the end of this time, the cells were washed
twice with VDMEM and incubated with the desired reagents (e.g.
FK506M, rapamycin or TGF-β) and 500 ng/mL Hoechst 33258 in 1 ml
VDMEM. After 1 h, 20 µl VDMEM reagent solution was placed on a
microscope slide and the coverslip was inverted onto this droplet. The
live cells were viewed through a 100× oil immersion objective on a Leitz
Laborlux S 100W Hg fluorescence microscope and images were cap-
tured with a Hitachi HV-C12 CCD camera using Flashpoint FPG v2.50
software. Fluorescein filters were used to record GFP images and no
filter was used for Hoechst 33258 images. Images shown in the figures
are representative of most cells in a given experiment. Each experiment
was performed multiple times and the results were consistent.
Luciferase assay 
Mv1Lu mink lung epithelial cells were obtained from the American Type
Culture Collection (catalog #CCL64) and DR26 cells were obtained
from Joan Massague. Both cell lines were cultured in DMEM with 10%
FBS, 100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulfate
and 100 µM each of the amino acids Ala, Asp, Glu, Gly, Asn, and Pro
(three-letter amino acid codes). 2 × 105 mink lung cells (either Mv1Lu
or DR26) were seeded in each well of a 6 well dish. After 24 h, cells
were transfected using DEAE-dextran. For each well, 250 ng p3TPLux
DNA was mixed with 250 ng each receptor DNA (750 ng total DNA),
6 µl 10 mM chloroquine, 7.5 µl 10 mg/ml DEAE-dextran and 600 µl
minimal essential medium (MEM) supplemented with the nonessential
amino acids (NEAA) and incubated at room temperature for 10 min.
The cells were washed twice with MEM and the DNA complexes were
added to the cells and incubated at 37°C with 5% CO2 for 3 h. The
cells were then shocked with 1 ml of 10% DMSO in PBS for 2 min,
washed twice with Hank's Balanced Salt Solution (HBSS) and incu-
bated in growth media at 37 °C with 5% CO2. After 20 h, the cells
were washed once and incubated in DMEM containing 0.2% FBS and
100 µM each of the amino acids Ala, Asp, Glu, Gly, Asn, and Pro and
Supplementary material
the reagent of interest (e.g. FK506M, rapamycin or TGF-β) for
25–30 h. Cells were incubated on ice for 15 min, washed three times
with HBSS and lysed in extraction buffer (25 mM glycylglycine, pH 7.8,
15 mM MgSO4, 4 mM EGTA, 1% Triton X, 1 mM DTT, 1 mM PMSF)
by shaking gently at 4 °C for 30 min. The lysates were centrifuged for
5 min at 10,000 × g at 4 °C and stored on ice. Lysate (100 µl) was
added to 150 µl assay mixture (25 mM glycylglycine pH 7.8, 15 mM
MgSO4, 4 mM EGTA, 15 mM K2HPO4 pH 7.8, 1 mM DTT, 4 mM ATP)
and 150 µl luciferin buffer (25 mM glycylglycine pH 7.8, 15 mM
MgSO4, 4 mM EGTA, 10 mM DTT, 167 µM D-luciferin). This mixture
was placed in a 500 µl microfuge tube inside a glass scintillation vial,
and luminescence was detected by counting in single photon mode
(SPM) on a Beckman LS 6500 liquid scintillation counter for 15 sec.
The error bars reported represent plus or minus one standard devia-
tion. All experiments were performed multiple times in triplicate
S2 Supplementary material
Figure S1
Structures of the homodimerizers FK1012H2
and CsA2, the heterodimerizers FKCsA and
rapamycin, and the FKBP12 and cyclophilin
antagonists FK506M and CsAM, respectively.
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Figure S2
A cartoon diagram of FK1012H2-induced
oligomerization of the MFpk3TIT202D protein
stably expressed in mink lung cells.
Oligomerization of the type I receptor tail
inhibits the growth of the stable cell line. For
simplicity, a single FKBP12 domain is shown,
although the construct M(Fpk)3TIT202D contains
three tandem FKBP12 domains.
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